The US-listed company Sonnet will merge to establish Hyperliquid Strategies and launch a capital strategy, holding 12.6 million HYPE and 300 million in cash.

robot
Abstract generation in progress

BlockBeats news, on July 14, according to The Block, Nasdaq-listed Sonnet BioTherapeutics has agreed to an $888 million merger deal, will be renamed Hyperliquid Strategies, and launch the HYPE fund strategy. The Nasdaq-listed Sonnet BioTherapeutics has agreed to merge with Rorschach I LLC to form Hyperliquid Strategies and initiate the fund strategy. According to a press release issued on Monday, Rorschach I LLC is a newly formed company by affiliated entities of Atlas Merchant Capital LLC, Paradigm Operations LP, and other sponsors. Upon completion of the transaction, the new entity will be renamed Hyperliquid Strategies, which is expected to hold 12.6 million HYPE Tokens and $305 million in cash, with a total valuation of approximately $888 million. The transaction has strategic investors participating, including Paradigm, Galaxy Digital, Pantera Capital, D1 Capital, Republic Digital, and 683 Capital. After the merger is completed, Hyperliquid Strategies will continue to trade on Nasdaq, with a change in stock code, becoming a publicly listed Crypto Assets fund company.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate app
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)